CD274 and neoplasm: Finally, as a real-world clinical study, long-term follow-up is required to obtain more treatment data, such as PD-1 or PD-L1 intensity of tumor tissues and follow-up imaging data to assess responses of patients with BoM to treatment, which may be conducive to identifing biomarkers of BMAs plus immunotargeted therapy for patients with HCC and BoM.